DHMOF方案治疗肺腺癌46例近期疗效观察

• 作 者: 陈力 刘淑真 白振芬 方世勤 蒋英华
• 机 构: 河南省肿瘤医院,河南省肿瘤医院,河南省肿瘤医院,河南省肿瘤医院,河南省肿瘤医院,
• 出 处: 河南肿瘤学杂志
• 发表日期: 1991年04期
• 关键词: 肺腺癌 DHMOF 近期疗效观察 肿瘤死亡率 非小细胞肺癌 化疗敏感性 微管蛋白 联合化疗 肺癌病人 手足麻木

原发性支气管肺癌占我国男性恶性肿瘤死亡率的第4位,女性恶性肿瘤死亡率的第5位,是常见肿瘤之一。其中,肺腺癌占20～40％。由于不少患者确诊时已失去手术机会,放疗又不敏感,因而探索一种治疗肺腺癌有效的化疗方案十分必要。我们自1985年6月～1990年1月用DHMOF方案治疗中晚期肺腺癌46例,报告如下。

Primary bronchogenic carcinoma accounts for the fourth highest mortality rate of male malignant tumors in China, and the fifth highest mortality rate for female malignant tumors. It is one of the most common cancers. Among them, lung adenocarcinoma accounts for 20 to 40%. Since many patients have lost surgery when they are diagnosed and radiotherapy is not sensitive, it is necessary to explore an effective chemotherapy for lung adenocarcinoma. We used the DHMOF regimen for treatment of 46 cases of advanced lung adenocarcinoma from June 1985 to January 1990. The report is as follows.